Presseportal.de - Abbott Laboratorieshttp://www.presseportal.de/pm/21683/abbott-laboratories/rssPresseportal.de: Abbott Laboratories (Digitale Pressemappe)de-denews aktuell GmbHhttp://www.presseportal.de/images/logo_napresseportal.gifPresseportal.de - Abbott Laboratorieshttp://www.presseportal.de/pm/21683/abbott-laboratories/rssredaktion@presseportal.de (Jens Petersen)Sat, 11 Feb 2012 02:17:13 +0100Wed, 19 Oct 2011 15:00:30 +02006Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based PharmaceuticalsAbbott Laboratories: Abbott Park, Illinois (ots/PRNewswire) - - Two publicly traded companies will offer shareholders distinct opportunities given unique investment identities, business profiles and attributes ...http://www.presseportal.de/pm/21683/2132595/abbott-to-separate-into-two-leading-companies-in-diversified-medical-products-and-research-based/rssWed, 19 Oct 2011 15:00:30 +0200http://www.presseportal.de/pm/21683/2132595/abbott-to-separate-into-two-leading-companies-in-diversified-medical-products-and-research-based/rss Abbott Laboratories [Pressemappe]
Abbott Park, Illinois (ots/PRNewswire) - - Two publicly traded companies will offer shareholders distinct opportunities given unique investment identities, business profiles and attributes ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott Confirms Long-Term Commitment to HIV Care with the Planned Development of New FormulationsAbbott Laboratories: Abbott Park, Illinois (ots/PRNewswire) - Abbott announced today that it plans to develop two new formulations of its HIV medicines, Kaletra (lopinavir/ritonavir) and Norvir (ritonavir), to offer new formulation options for people living with HIV-1. ...http://www.presseportal.de/pm/21683/2079912/abbott-confirms-long-term-commitment-to-hiv-care-with-the-planned-development-of-new-formulations/rssFri, 15 Jul 2011 15:15:52 +0200http://www.presseportal.de/pm/21683/2079912/abbott-confirms-long-term-commitment-to-hiv-care-with-the-planned-development-of-new-formulations/rss Abbott Laboratories [Pressemappe]
Abbott Park, Illinois (ots/PRNewswire) - Abbott announced today that it plans to develop two new formulations of its HIV medicines, Kaletra (lopinavir/ritonavir) and Norvir (ritonavir), to offer new formulation options for people living with HIV-1. ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott Enhances Pharmaceutical Pipeline with Acquisition of Facet BiotechAbbott Laboratories: ABBOTT PARK, Illinois and REDWOOD CITY, California, March 9, 2010 (ots/PRNewswire) -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical ...http://www.presseportal.de/pm/21683/1575044/abbott-enhances-pharmaceutical-pipeline-with-acquisition-of-facet-biotech/rssTue, 09 Mar 2010 22:55:10 +0100http://www.presseportal.de/pm/21683/1575044/abbott-enhances-pharmaceutical-pipeline-with-acquisition-of-facet-biotech/rss Abbott Laboratories [Pressemappe]
ABBOTT PARK, Illinois and REDWOOD CITY, California, March 9, 2010 (ots/PRNewswire) -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesTwenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health CrisisAbbott Laboratories: Abbott Park, Illinois, March 2, 2010 (ots/PRNewswire) - Imagine delaying a life-saving surgery or being afraid to receive or donate blood for fear of contracting HIV (http://www.who.int/hiv/en/). It seems unbelievable today, but twenty-five years ...http://www.presseportal.de/pm/21683/1570525/twenty-five-years-of-hiv-blood-testing-helped-to-positively-transform-global-health-crisis/rssTue, 02 Mar 2010 13:32:25 +0100http://www.presseportal.de/pm/21683/1570525/twenty-five-years-of-hiv-blood-testing-helped-to-positively-transform-global-health-crisis/rss Abbott Laboratories [Pressemappe]
Abbott Park, Illinois, March 2, 2010 (ots/PRNewswire) - Imagine delaying a life-saving surgery or being afraid to receive or donate blood for fear of contracting HIV (http://www.who.int/hiv/en/). It seems unbelievable today, but twenty-five years ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott Completes Acquisition of Solvay PharmaceuticalsAbbott Laboratories: Abbott Park, Illinois, February 16, 2010 (ots/PRNewswire) - Abbott today announced that it has completed its EUR 4.5 billion (US$6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary ...http://www.presseportal.de/pm/21683/1562146/abbott-completes-acquisition-of-solvay-pharmaceuticals/rssTue, 16 Feb 2010 07:31:25 +0100http://www.presseportal.de/pm/21683/1562146/abbott-completes-acquisition-of-solvay-pharmaceuticals/rss Abbott Laboratories [Pressemappe]
Abbott Park, Illinois, February 16, 2010 (ots/PRNewswire) - Abbott today announced that it has completed its EUR 4.5 billion (US$6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott to Suspend Marketing of Obesity Medicine Sibutramine in European Union CountriesAbbott Laboratories: Abbott Park, Illinois (ots/PRNewswire) - Today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted to recommend the suspension of marketing authorizations for all anti-obesity medicines containing ...http://www.presseportal.de/pm/21683/1548548/abbott-to-suspend-marketing-of-obesity-medicine-sibutramine-in-european-union-countries/rssThu, 21 Jan 2010 21:55:25 +0100http://www.presseportal.de/pm/21683/1548548/abbott-to-suspend-marketing-of-obesity-medicine-sibutramine-in-european-union-countries/rss Abbott Laboratories [Pressemappe]
Abbott Park, Illinois (ots/PRNewswire) - Today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted to recommend the suspension of marketing authorizations for all anti-obesity medicines containing ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic TestAbbott Laboratories: Abbott Park, Illinois (ots/PRNewswire) - A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the ...http://www.presseportal.de/pm/21683/1544531/abbott-receives-european-regulatory-approval-for-new-ovarian-cancer-diagnostic-test/rssThu, 14 Jan 2010 15:31:35 +0100http://www.presseportal.de/pm/21683/1544531/abbott-receives-european-regulatory-approval-for-new-ovarian-cancer-diagnostic-test/rss Abbott Laboratories [Pressemappe]
Abbott Park, Illinois (ots/PRNewswire) - A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesNew Abbott Gene-Based Test for Colorectal Cancer Receives CE MarkAbbott Laboratories: Des Plaines, Illinois (ots/PRNewswire) - Abbott announced today it has received CE Marking (Conformite Europeene) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non-invasive DNA assay that ...http://www.presseportal.de/pm/21683/1540418/new-abbott-gene-based-test-for-colorectal-cancer-receives-ce-mark/rssWed, 06 Jan 2010 20:27:25 +0100http://www.presseportal.de/pm/21683/1540418/new-abbott-gene-based-test-for-colorectal-cancer-receives-ce-mark/rss Abbott Laboratories [Pressemappe]
Des Plaines, Illinois (ots/PRNewswire) - Abbott announced today it has received CE Marking (Conformite Europeene) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non-invasive DNA assay that ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International TrialAbbott Laboratories: Orlando, Florida, November 16 (ots/PRNewswire) - - New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients Abbott (NYSE: ABT) today announced three-year data from the first 30 patients in ...http://www.presseportal.de/pm/21683/1513240/abbott-announces-positive-three-year-data-on-its-fully-bioabsorbable-stent-technology-initiates/rssMon, 16 Nov 2009 21:06:45 +0100http://www.presseportal.de/pm/21683/1513240/abbott-announces-positive-three-year-data-on-its-fully-bioabsorbable-stent-technology-initiates/rss Abbott Laboratories [Pressemappe]
Orlando, Florida, November 16 (ots/PRNewswire) - - New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients Abbott (NYSE: ABT) today announced three-year data from the first 30 patients in ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott to Acquire Solvay Pharmaceuticals BusinessAbbott Laboratories: Abbott Park, Illinois (ots/PRNewswire) - - Diversifies Abbott's pharmaceutical products, expanding international growth platform - Supports long-term strategy to bolster presence in key global emerging markets - Adds substantial R&D spending ...http://www.presseportal.de/pm/21683/1483062/abbott-to-acquire-solvay-pharmaceuticals-business/rssMon, 28 Sep 2009 07:50:35 +0200http://www.presseportal.de/pm/21683/1483062/abbott-to-acquire-solvay-pharmaceuticals-business/rss Abbott Laboratories [Pressemappe]
Abbott Park, Illinois (ots/PRNewswire) - - Diversifies Abbott's pharmaceutical products, expanding international growth platform - Supports long-term strategy to bolster presence in key global emerging markets - Adds substantial R&D spending ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesResults from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery DiseaseAbbott Laboratories: San Francisco (ots/PRNewswire) - Abbott (NYSE: ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first ...http://www.presseportal.de/pm/21683/1481846/results-from-abbott-s-prospect-study-provide-new-insight-into-role-of-vulnerable-plaque-in-coronary/rssThu, 24 Sep 2009 21:30:47 +0200http://www.presseportal.de/pm/21683/1481846/results-from-abbott-s-prospect-study-provide-new-insight-into-role-of-vulnerable-plaque-in-coronary/rss Abbott Laboratories [Pressemappe]
San Francisco (ots/PRNewswire) - Abbott (NYSE: ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE TrialAbbott Laboratories: San Francisco (ots/PRNewswire) - - Independent Study of 1,800 Patients Affirms Outstanding Performance of XIENCE V vs. TAXUS Liberte Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading ...http://www.presseportal.de/pm/21683/1481085/abbott-s-xience-v-r-demonstrates-significantly-lower-rates-of-mace-and-stent-thrombosis-compared-to/rssWed, 23 Sep 2009 23:16:02 +0200http://www.presseportal.de/pm/21683/1481085/abbott-s-xience-v-r-demonstrates-significantly-lower-rates-of-mace-and-stent-thrombosis-compared-to/rss Abbott Laboratories [Pressemappe]
San Francisco (ots/PRNewswire) - - Independent Study of 1,800 Patients Affirms Outstanding Performance of XIENCE V vs. TAXUS Liberte Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading ... Lesen Sie hier weiter...
]]>Finanzenredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV TrialAbbott Laboratories: San Francisco (ots/PRNewswire) - At One Year, XIENCE V Demonstrates: - Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS - 74 Percent Reduction in Stent Thrombosis (Blood Clots) ...http://www.presseportal.de/pm/21683/1481063/abbott-s-xience-v-r-superior-to-taxus-r-in-key-safety-and-efficacy-measures-in-spirit-iv-trial/rssWed, 23 Sep 2009 20:15:40 +0200http://www.presseportal.de/pm/21683/1481063/abbott-s-xience-v-r-superior-to-taxus-r-in-key-safety-and-efficacy-measures-in-spirit-iv-trial/rss Abbott Laboratories [Pressemappe]
San Francisco (ots/PRNewswire) - At One Year, XIENCE V Demonstrates: - Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS - 74 Percent Reduction in Stent Thrombosis (Blood Clots) ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III TrialAbbott Laboratories: San Francisco (ots/PRNewswire) - - Market-Leading XIENCE V Demonstrates Single-Digit Rate of Major Adverse Cardiac Events (MACE) at Three Years and a 43 Percent Reduction vs. TAXUS - No Additional Stent Thrombosis between Two and Three Years, and ...http://www.presseportal.de/pm/21683/1479471/abbott-s-xience-v-r-continues-to-outperform-taxus-with-sustained-clinical-advantages-and-impressive/rssMon, 21 Sep 2009 17:07:25 +0200http://www.presseportal.de/pm/21683/1479471/abbott-s-xience-v-r-continues-to-outperform-taxus-with-sustained-clinical-advantages-and-impressive/rss Abbott Laboratories [Pressemappe]
San Francisco (ots/PRNewswire) - - Market-Leading XIENCE V Demonstrates Single-Digit Rate of Major Adverse Cardiac Events (MACE) at Three Years and a 43 Percent Reduction vs. TAXUS - No Additional Stent Thrombosis between Two and Three Years, and ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesAbbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International MarketsAbbott Laboratories: Barcelona, Spain (ots/PRNewswire) - - New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes - Built Upon the Proven Track Record of Superior Clinical Outcomes of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent ...http://www.presseportal.de/pm/21683/1466377/abbott-launches-next-generation-xience-prime-tm-drug-eluting-stent-in-international-markets/rssMon, 31 Aug 2009 09:07:45 +0200http://www.presseportal.de/pm/21683/1466377/abbott-launches-next-generation-xience-prime-tm-drug-eluting-stent-in-international-markets/rss Abbott Laboratories [Pressemappe]
Barcelona, Spain (ots/PRNewswire) - - New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes - Built Upon the Proven Track Record of Superior Clinical Outcomes of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas Technologies